MET vs TGTX · P/E 13, rev $38.23B vs P/E 18, rev $240.3M
MetLife Inc (MET) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
MetLife Inc (MET) is a insurance - life company listed on US.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
MET currently screens at market cap $52.16B and trailing P/E 12.7. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the MET and TGTX stock pages for the full models.
Not investment advice.